AstraZeneca Halts NXY-059 Development Following SAINT II Stroke Results
This article was originally published in The Pink Sheet Daily
Executive Summary
Firm returns the neuroprotectant to partner Renovis after pivotal trial in acute ischemic stroke fails to show statistical significance.